Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for APR-1051 in Solid tumor/s, Cancer. The expected timing is based on the latest available company guidance and may change.
ACESOT-1051 trial. 3/11/24- IND cleared. 6/17/24- Dosed first patient. 8/12/25- Completion of DE phase in H1 2026. 10/24/25- Presented clinical update at AACR-NCI-EORTC’25. 11/12/25:- Early Ph1 data; dose escalation to 150 mg; DE completion expected H1 2026. 02/18/26:- Ph1 ACESOT-1051 showed second unconfirmed PR and multiple SD; next data update expected Q2 2026. 03/16/26:- Two uPRs and five SD in ACESOT-1051; dose level 8 ongoing; next data update Q2 2026. 03/30/26:- Confirmed partial response at 220 mg; dose escalation to 300 mg planned Q2 2026; further update Q2 2026. 04/21/26:- ASCO 2026 abstract accepted; ACESOT-1051 early results poster May 30, 2026 (NCT06260514). 05/13/26:- Two PRs including one confirmed; ASCO 2026 poster May 30; dose escalation completion anticipated Q2 2027. 06/01/26:- Updated ACESOT-1051 ASCO data; dose escalation ongoing; completion of escalation/backfill expected Q2 2027. 07/30/26:- Next Ph1 data update expected at a medical meeting in Q4 2026. Dose escalation/backfill completion expected Q2 2027. 08/12/26:- ACESOT-1051 enrollment is accelerating. Next Phase 1 data update will occur in Q4 2026; escalation/backfill completion is expected in Q2 2027.
Verification
Confirm timing and program details against the company announcement or filing.